DYN vs SRPT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DYN and SRPT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DYN and SRPT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Dyne Therapeutics (Nasdaq: DYN) is a clinical-stage biotech building targeted therapies for genetically driven muscle diseases using its FORCE platform, which links an oligonucleotide payload to a fragment that binds the transferrin receptor 1 (TfR1) to deliver drug efficiently into skeletal, cardiac and smooth muscle. Its two lead programs are z-rostudirsen (formerly DYNE-251), an exon 51 skipping therapy for Duchenne muscular dystrophy (DMD), and z-basivarsen (formerly DYNE-101) for myotonic dystrophy type 1 (DM1), with earlier candidates in facioscapulohumeral dystrophy (FSHD) and Pompe disease behind them.

Full DYN guide

Sarepta Therapeutics is a biotechnology company focused almost entirely on Duchenne muscular dystrophy (DMD), a fatal muscle-wasting genetic disease. Its portfolio has two pillars: Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for DMD delivered with the AAVrh74 viral vector, and an older RNA-based exon-skipping franchise (Exondys 51, Vyondys 53, Amondys 45) that treats subsets of patients by helping cells skip faulty sections of the dystrophin gene. Roche holds ex-US commercialization rights to Elevidys, which produces meaningful licensing and royalty revenue for Sarepta. The company reiterated 2026 net product revenue guidance of roughly $1.2 billion to $1.4 billion.

Full SRPT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DYN drivers: DMD z-rostudirsen approaching the FDA; DM1 z-basivarsen as a second pillar.
• SRPT drivers: Elevidys franchise durability; Cash-generative base RNA business.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Dyne is unprofitable and burning cash, posting a net loss of about $121M in Q1 2026 on effectively no product revenue, so its market value rests entirely on future clinical and regulatory success. For SRPT, the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DYN if you believe its drivers more; SRPT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DYN and SRPT guides.

DYN. Dyne has no P/E because it is unprofitable and pre-revenue, so investors typically frame it on cash-versus-market-cap and the probability-weighted value of its pipeline. A meaningful slice of the roughly $3.9B market value is backed by its ~$972M cash balance, with the remainder pricing the DMD and DM1 opportunity. Because there are no earnings to anchor the shares, the stock trades on regulatory milestones and trial data rather than fundamentals, which drives high volatility.

SRPT. SRPT's market cap fell roughly 80 percent from over $11 billion in early 2025 to around $2 billion by mid-2026 as the Elevidys safety events reset expectations. The company remains a real revenue-generating biotech with reiterated 2026 net product revenue guidance of roughly $1.2 billion to $1.4 billion and a cash cushion. Valuation now reflects deep uncertainty about gene-therapy adoption rather than a going-concern question about the base RNA business.

Headline figures (approximate, July 2026): DYN shows market cap ~$3.9B, share price ~$23, product revenue ~$0 (pre-commercial), net loss (q1 2026) ~$121M; SRPT shows market cap ~$2.1B, 2026 revenue guidance ~$1.2B-$1.4B, cash & investments ~$748M, 2026 non-gaap expense outlook ~$800M-$900M.

DYN and SRPT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DYN and SRPT exposure against your real portfolio. It is not an investment adviser.